955029-45-5

Usage

Uses

Used in Pharmaceutical Industry:
(2-methyl-2-pyrrolidinyl)methanol(SALTDATA: FREE) is used as a chiral auxiliary for creating enantiomerically pure compounds, which is crucial for the development of effective and safe medications.
Used in Chemical Industry:
(2-methyl-2-pyrrolidinyl)methanol(SALTDATA: FREE) is used as a building block in the synthesis of various organic compounds, contributing to the creation of new materials and products.
Used in Drug Synthesis:
(2-methyl-2-pyrrolidinyl)methanol(SALTDATA: FREE) is used as a key component in the synthesis of various drugs, aiding in the development of new therapeutic agents.
Used in Central Nervous System Disorder Treatment:
(2-methyl-2-pyrrolidinyl)methanol(SALTDATA: FREE) has been studied for its potential therapeutic effects in the treatment of central nervous system disorders, offering a promising avenue for medical research and treatment options.

Upstream product

• 16277-06-8 α-methylproline 
• 1290048-17-7 2-Hydroxymethyl-2-methyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 145681-01-2 (+/-)-N-tert-butoxycarbonylproline methyl ester 
• 201406-78-2 1-benzylpyrrolidine-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Tricyclic dihydroimidazopyrimidinone derivative, and preparation method, pharmaceutical composition and application thereof

The invention provides a compound as shown in a general formula (I), cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the compound as aLp-PLA2 inhibitor, wherein R1, R2, Rx, Ra, Q, U, X, Y, m, n and A are defined in the specification.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

PYRAZOL DERIVATIVES

The invention is concerned with novel pyrazol derivatives of formula (I), wherein R1, R2, R3, R4, X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.